Incyte stock holds firm as quarterly revenue jumps 37.7 percent
Published on 09/14/2026 at 12:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte Corporation stock (ISIN US45337C1027) is trading close to USD 121 on Nasdaq as of September 14, 2026, valuing the biopharmaceutical group at about USD 24.6 billion and reflecting investors’ focus on its latest strong quarterly figures.
Quarterly earnings beat expectations
According to MarketBeat on September 14, 2026, Incyte recently reported quarterly earnings per share of USD 3.09, clearly ahead of market expectations for the period.
In the same quarterly report, revenue reached USD 1.67 billion, representing an increase of 37.7 percent year over year, which underlines how strongly the company has grown its top line compared with the prior year’s corresponding quarter.MarketBeat
Institutional moves and analyst view
As MarketBeat reports on September 14, 2026, National Pension Service reduced its position in Incyte by 44.9 percent in the second quarter, selling 34,758 shares and retaining 42,731 shares valued at around USD 4.84 million.
The same overview highlights that institutional investors collectively hold 96.97 percent of Incyte’s outstanding shares, indicating that the stock remains heavily owned by large professional investors.MarketBeat
Analysts currently maintain a Moderate Buy consensus on Incyte stock, with an average price target of USD 124.05 according to MarketBeat, which is modestly above the recent trading level.
Stock valuation and trading range
Per the latest stock performance snapshot cited by MarketBeat, Incyte shares opened at USD 121.47, which places the stock roughly in the middle of its 52-week trading corridor between a low of USD 81.09 and a high of USD 132.60.
At this level, Incyte is valued at a price-earnings ratio of 15.47 based on the reported earnings, and the company’s shares trade with a beta of 0.77, signaling somewhat lower volatility than the broader market.MarketBeat
Closing price and investor takeaway
On Nasdaq, Incyte stock most recently traded around USD 121.47 on September 14, 2026, leaving the shares less than USD 11 below the 52-week high of USD 132.60 and offering investors a combination of robust recent earnings growth and an analyst target that still sits slightly above the current price.
Incyte stock key data
- Company: Incyte Corporation
- ISIN: US45337C1027
- Ticker: INCY
- Trading venue: Nasdaq
- Price (as of September 14, 2026): 121.47 USD
- Market capitalization: 24.62 billion USD (as of September 14, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
